The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing

Highlights from the PER® CME activity "The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Seth A. Wander, MD, PhD, Reshma L. Mahtani, DO, and Shanu Modi, MD, review pivotal data regarding the use of antibody-drug conjugates in the treatment of metastatic triple-negative breast cancer, and discuss how they apply these data in the management of their patients.

Earn CME credit by completing the full accredited activity (available through July 31, 2027): https://www.gotoper.com/courses/the-adc-revolution-in-metastatic-breast-cancer-redefining-treatment-selection-and-sequencing-kppp
This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.